This article first appeared on GuruFocus .
Release Date: May 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Anaergia Inc ( ANRGF ) reported a 122% year-over-year revenue growth for Q1 2026.
-
The company achieved a 135% increase in gross profit compared to Q1 2025.
-
Anaergia Inc ( ANRGF ) recorded its third consecutive quarter of positive adjusted EBITDA.
-
The revenue backlog increased to $265 million, marking a 32% rise compared to Q1 2025.
-
The company entered the hydro-treated vegetable oil market, expanding its business verticals.
Negative Points
-
Anaergia Inc ( ANRGF ) reported a net loss of $4.4 million for Q1 2026.
-
The Rhode Island Bioenergy Facility's ramp-up process negatively impacted gross margins by approximately $2 million.
-
O&M service revenue was down modestly year-over-year due to fewer service activities in North America.
-
The company is still working on operational improvements at the Rhode Island facility to reach full potential.
-
Despite positive EBITDA, the company continues to face challenges in achieving profitability across all segments.
Q & A Highlights
Q: Given the better-than-expected execution in Q1, could you help us understand how much of the revenue outperformance was due to accelerated project timings versus a steady step-up in execution capacity? Also, how should we think about the core cadence of capital conversion for the rest of the year, particularly across the largest European projects? A: We are seeing a continued cadence of bookings year-over-year. While there may be inter-quarter shifts, the trend is a substantial increase in backlog. Most projects take about a year and a half to two years to execute fully. Our recognition of revenue is consistent with this timeline, and we expect continued growth in our backlog and capital sales.
Q: On the O&M service side, revenue was down modestly year-over-year. Was this primarily timing-related, or due to resources being redeployed to larger capital sales execution opportunities? Do you expect the O&M business to resume a stable growth trajectory? A: The O&M business remains a pillar of our revenue growth. The shifts in figures are mostly timing-related. Our capital-light strategy involves shifting risk out of operating agreements, which can cause variability. We expect the O&M business to grow as an add-on service to clients who purchase systems from us.
Q: Could you discuss the significance of the Canadian CFR negative CI approval for the Rhode Island facility from a monetization perspective? A: The approval is a validation and market advantage for us and our clients. It allows the facility to participate in monetizing CFR credits, enhancing top-line revenue. We anticipate a roughly 30% increase in the gas sale price as a result, with further enhancements expected as we convert to a permanent CI score.
Q: As you continue to scale the business, where do you see areas for driving operating leverage, such as SG&A reductions or margin improvements? A: We continue to focus on projects in our capital sales business, which has very nice margins. The Rhode Island facility's CI score approval will improve margins and adjusted EBITDA. We have leverage in the market due to our technology platform, and we aim to grow the top-line while keeping SG&A costs down.
Q: What is the expected timeline for the full ramp-up of the Rhode Island facility, and when can we expect a positive contribution to the overall earnings profile? A: We are working on improvements, particularly on the feedstock side, and aim to hit profitability by year-end. This involves timing with enhanced credit monetization and optimizing feedstock mix. We expect improvements quarter-over-quarter towards this goal.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
